literature

HIV mutation literature information.

HIV-1 Drug Resistance in ART-Naive Individuals in Myanmar.

PMID: 32368103 2020 Infection and drug resistance

Discussion: Furthermore, we found that the major NNRTI-related SDRMs were K101P, K103N, V106A, E138A, Y181C, and Y188H, and the major NRTI-related SDRMs were L74V/I and M184V.

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.

PMID: 32280691 2020 BioMed research international

Result: The most commonly observed mutations with NRTIs were M184I/V (59.59%, 146/245), K65R (28.16%, 69/245), D67N/G (19.18%, 47/245), K70E/K/R (17.14%, 42/245), Y115F (15.10%, 37/245), L74I/V (11.02%, 27/245), and T215I/Y (8.16%, 20/245).

Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study.

PMID: 32576136 2020 BMC infectious diseases

Figure: Note: PIs mutations: M46I, I54V, V82A, K20T, L10F/LFI and Q58E/QE; NRTIs mutations: D67N/DN, K70R/KR/T, M184V/MV/I, T215F/FS/TNSY, K219Q, K65R, L74I/LI/LV, Y115F, L210W, M41L and V75I; NNRTIs mutation:

PMID: 31024744 2019 Acta naturae

Result: The mutation L74I specific to IN_A was found only in 4% of the sequences of CRF63_02A1 IN.

High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.

PMID: 30891603 2019 The Journal of antimicrobial chemotherapy

Abstract: Two (2/18; 11.1%) viruses from children treated with a first-line regimen had INSTI DRMs at codon 138 (E138K and E138T), which is known to harbour major resistance mutations, and also had the accessory mutations L74I, G140K, G140R and G163R.

Result: Another HIV-1 strain displayed the accessory mutations G140R and L74I, and three APOBEC-related mutations: G70R, G149R and G247R.

Discussion: Along with the DRMs displayed at codon 138, the polymorphic accessory mutations G140K, G140R, <

Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naive and Experienced Individuals from Western India.

PMID: 30793915 2019 AIDS research and human retroviruses

Abstract: Other accessory mutations were L74IM (34.48%), Q95K (1.72%), and T97A (1.72%).

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.

PMID: 30871487 2019 BMC infectious diseases

Result: Of note, L74I (following exposure to TDF-containing regimens) and L210 W (following exposure to regimens containing a thymidine analogue) mutations were found only in the group of patients infected with CRF02_AG viruses.

Discussion: Even though the analysis of CRF02_AG versus non-AG showed no major effect of the local subtype distribution on emerging DRMs, molecular epidemiology surveillance merits further investigations, which include the preferential pattern of L74I as a potential signature in CRF02_AG-infected patients.

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

PMID: 29846534 2019 Clinical infectious diseases

Result: The non-TAMs K65R, L74V/I, Y115F, and Q151M each occurred in just 1 or 2 individuals.

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

PMID: 30650082 2019 PloS one

Result: A Kaplan-Meier analysis could be performed for 18 TDRMs (K20T, L23I, K43T, M46I/L/V, I54V, M41L, L74I, M184V, L210W, K219R, T215A/C/D/N/S and T215Y).

Discussion: In contrast, the mean survival times determined for NRTI mutations T215Y/A/N and L74I, which were also found at a lower proportion among the transmitted NRTI mutations, ranged from 1.0 to 1.7 years.

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.

PMID: 30380053 2019 The Journal of antimicrobial chemotherapy

Result: Fifteen participants had integrase DRM20% (15/83, 18.1%), including Q148R conferring low-level resistance to dolutegravir, and some accessory integrase mutations were also found: L74I/M (n = 12/15, 80.0%), E157Q (n = 1) and G163R (n = 1).

Result: While no major mutation was described for dolutegravir resistance, we found some accessory integrase mutations in 98/524 (18.7%), such as L74I/M (n = 81/98, 82.7%), T97A (n = 8/98, 8.2%) and E157Q (n = 5/98, 5.1%), and more sporadically E138D/K (n = 2), V151I (n = 1) and G163R

Browser Board

Co-occurred Entities

Filtrator